Development and partial characterization of a human T-lymphoblastic leukemic (CCRF-CEM) cell line resistant to etoposide. Analysis of possible circumventing approaches

Journal of Chemotherapy
C FlandinaN D'Alessandro

Abstract

We have selected an etoposide-resistant variant (CCRF-CEM/VP-16) of the human T-lymphoblastic CCRF-CEM leukemia for study. Resistance to the topoisomerase II (topo II) inhibitor was about 11-fold and stable. Other data revealed that the new cell line had acquired an atypical, non-P-glycoprotein overexpressing multidrug resistant (MDR) phenotype with cross-resistance to other topo II inhibitors (amsacrine, doxorubicin, and mitoxantrone) and to glucocorticoids, but not to novobiocin, ICRF-187, vincristine or cisplatin. In a first instance, we assumed that altered drug-topo II interactions, based on quantitative and/or qualitative modifications of the enzyme, are a cause of resistance in the cell line. We tried to modify the drug sensitivity of the cells by means of various agents and cytokines. Positive results were obtained with verapamil and, to a lesser extent, cyclosporin A, but they were not specific for the drug resistant variant and occurred in the parental CCRF-CEM as well. Other attempts with buthionine sulfoximine, novobiocin, pentoxifylline, interleukin-1, interferon-alpha, retinoic acid, TNF-alpha, bryostatin 1 or phorbol myristate acetate were substantially unsuccessful, thus confirming the difficulty of pharmacologi...Continue Reading

References

Oct 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·A SuginoN R Cozzarelli
Jan 1, 1991·Life Sciences·P De IsabellaF Zunino
Sep 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·B Y BuggD P Suttle
Jan 1, 1990·Free Radical Research Communications·N Usui, B K Sinha
Jan 1, 1990·Advances in Pharmacology·E SchneiderL F Liu
Jan 1, 1989·New Directions for Mental Health Services·M R Callahan, D N Vocke
Nov 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·K B TanP S Schein
Apr 1, 1982·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·N Fox, G P Studzinski

❮ Previous
Next ❯

Citations

Jan 20, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S GrimaudoN D'Alessandro

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.